Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect and PK Study of BTD-001 in Healthy Volunteers
NCT03150498Phase 1Completed
- Sponsor
- Balance Therapeutics, Inc.
- Start
- May 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Pentetrazol in idiopathic hypersomnia (IH) and narcolepsy (2 arms), sponsored by Balance Therapeutics, Inc. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 2 more. Started May 2017; status: completed.
02
Drugs
Pentetrazol
03
Conditions
idiopathic hypersomnia (IH)narcolepsy
Beyond the preview
Go deeper on NCT03150498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03150498.